Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition

被引:137
|
作者
Bolden, Jessica E. [1 ]
Tasdemir, Nilgun [1 ,2 ,3 ]
Dow, Lukas E. [1 ]
van Es, Johan H. [4 ]
Wilkinson, John E. [5 ]
Zhao, Zhen [1 ]
Clevers, Hans [4 ,6 ]
Lowe, Scott W. [1 ,7 ]
机构
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA
[2] Watson Sch Biol Sci, Cold Spring Harbor, NY 11724 USA
[3] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA
[4] Hubrecht Inst, KNAW, NL-3584 CT Utrecht, Netherlands
[5] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA
[6] Univ Med Ctr Utrecht, NL-3584 CT Utrecht, Netherlands
[7] Howard Hughes Med Inst, New York, NY 10065 USA
来源
CELL REPORTS | 2014年 / 8卷 / 06期
基金
英国医学研究理事会;
关键词
RNA INTERFERENCE; GENE; MICE; BROMODOMAINS; CHROMATIN; TARGET; MYC; MAINTENANCE; EXPRESSION; CARCINOMA;
D O I
10.1016/j.celrep.2014.08.025
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
BET family proteins are novel therapeutic targets for cancer and inflammation and represent the first chromatin readers against which small-molecule inhibitors have been developed. First-generation BET inhibitors have shown therapeutic efficacy in preclinical models, but the consequences of sustained BET protein inhibition in normal tissues remain poorly characterized. Using an inducible and reversible transgenic RNAi mouse model, we show that strong suppression of the BET protein Brd4 in adult animals has dramatic effects in multiple tissues. Brd4-depleted mice display reversible epidermal hyperplasia, alopecia, and decreased cellular diversity and stem cell depletion in the small intestine. Furthermore, Brd4-suppressed intestines are sensitive to organ stress and show impaired regeneration following irradiation, suggesting that concurrent Brd4 suppression and certain cytotoxic therapies may induce undesirable synergistic effects. These findings provide important insight into Brd4 function in normal tissues and, importantly, predict several potential outcomes associated with potent and sustained BET protein inhibition.
引用
收藏
页码:1919 / 1929
页数:11
相关论文
共 50 条
  • [31] BROMODOMAIN PROTEIN BRD4 AS A POTENTIAL THERAPEUTIC TARGET IN SUNITINIB-RESISTANT RENAL CELL CARCINOMA
    Sakaguchi, Takashi
    Yoshino, Hirofumi
    Sugita, Satoshi
    Yonemori, Masaya
    Miyamoto, Kazutaka
    Osako, Youichi
    Tatarano, Shuichi
    Yamane, Takashi
    Nakagawa, Masayuki
    Enokida, Hideki
    JOURNAL OF UROLOGY, 2018, 199 (04): : E953 - E953
  • [32] Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies
    Jiang, Fei
    Wei, Qingyun
    Li, Huili
    Li, Hongmei
    Cui, Yong
    Ma, Yu
    Chen, Haifang
    Cao, Peng
    Lu, Tao
    Chen, Yadong
    BIOORGANIC & MEDICINAL CHEMISTRY, 2020, 28 (01)
  • [33] INTEGRATION OF CHROMATIN CONFORMATION, TRANSCRIPTOME AND GENOME-WIDE LANDSCAPE OF BRD2 AND BRD4 BINDING MOTIFS IDENTIFIES MECHANISMS OF BET INHIBITOR ACTION IN RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS
    Nagpal, S.
    Krishna, V.
    Yin, X.
    Pocalyko, D.
    Walsh, A.
    Bachman, K.
    Anderson, I.
    Madakamutil, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 192 - 192
  • [34] BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
    Ozer, Hatice Gulcin
    El-Gamal, Dalia
    Powell, Ben
    Hing, Zachary A.
    Blachly, James S.
    Harrington, Bonnie
    Mitchell, Shaneice
    Grieselhuber, Nicole R.
    Williams, Katie
    Lai, Tzung-Huei
    Alinari, Lapo
    Baiocchi, Robert A.
    Brinton, Lindsey
    Baskin, Elizabeth
    Cannon, Matthew
    Beaver, Larry
    Goettl, Virginia M.
    Lucas, David M.
    Woyach, Jennifer A.
    Sampath, Deepa
    Lehmann, Amy M.
    Yu, Lianbo
    Zhang, Jiazhong
    Ma, Yan
    Zhang, Ying
    Spevak, Wayne
    Shi, Songyuan
    Severson, Paul
    Shellooe, Rafe
    Carias, Heidi
    Tsang, Garson
    Dong, Ken
    Ewing, Todd
    Marimuthu, Adhirai
    Tantoy, Christina
    Walters, Jason
    Sanftner, Laura
    Rezaei, Hamid
    Nespi, Marika
    Matusow, Bernice
    Habets, Gaston
    Ibrahim, Prabha
    Zhang, Chao
    Mathe, Ewy A.
    Bollag, Gideon
    Byrd, John C.
    Lapalombella, Rosa
    CANCER DISCOVERY, 2018, 8 (04) : 458 - 477
  • [35] Unlocking the therapeutic potential of selective CDK7 and BRD4 inhibition against multiple myeloma cell growth
    Yao, Yao
    Deng, Shuhui
    Ng, Jessica Fong
    Yuan, Mei
    Chakraborty, Chandraditya
    Weiler, Vera Joy
    Munshi, Nikhil
    Fulciniti, Mariateresa
    HAEMATOLOGICA, 2025, 110 (01) : 153 - 162
  • [36] Bromodomain-Containing Protein 4 (BRD4) Inhibition Sensitizes Palomid 529-Induced Anti-Renal Cell Carcinoma Cell Activity in Vitro and in Vivo
    Xing, Zhao-yu
    Wang, Yin
    Cheng, Long
    Chen, Jie
    He, Xiao-zhou
    Xing, Wei
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2018, 50 (02) : 640 - 653
  • [37] Bromodomain-containing protein 4 (BRD4): a key player in inflammatory bowel disease and potential to inspire epigenetic therapeutics
    Ma, Zonghui
    Bolinger, Andrew A.
    Zhou, Jia
    Tian, Bing
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2023, 27 (01) : 1 - 7
  • [38] Integration of the Transcriptome and Genome-Wide Landscape of BRD2 and BRD4 Binding Motifs Identifies Key Superenhancer Genes and Reveals the Mechanism of Bet Inhibitor Action in Rheumatoid Arthritis Synovial Fibroblasts
    Krishna, Vinod
    Yin, Xuefeng
    Song, Qingxuan
    Walsh, Alice
    Pocalyko, David
    Bachman, Kurtis
    Anderson, Ian
    Madakamutil, Loui
    Nagpal, Sunil
    JOURNAL OF IMMUNOLOGY, 2021, 206 (02): : 422 - 431
  • [39] Targeting BRD4 with BET inhibition synergizes with anti-HER2 therapy and overcomes resistance in HER2-amplified uterine serous cancer
    Mahira, Shaheen
    Jawadi, Mohamad
    Karakilic, Huseyin
    Jones, Philip
    Baghaki, Hayriye
    Olawaiye, Alexander
    Mahdi, Haider
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S240 - S241
  • [40] Screening of an epigenetic compound library identifies BRD4 as a potential antiviral target for hepatitis B virus covalently closed circular DNA transcription
    Yu, Xiaoyang
    Long, Quanxin
    Shen, Sheng
    Liu, Zhentao
    Chandran, Jithin
    Zhang, Junjie
    Ding, Hao
    Zhang, Hu
    Cai, Dawei
    Kim, Elena S.
    Huang, Yufei
    Guo, Haitao
    ANTIVIRAL RESEARCH, 2023, 211